KR20140116879A - (3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합 - Google Patents

(3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합 Download PDF

Info

Publication number
KR20140116879A
KR20140116879A KR1020147020364A KR20147020364A KR20140116879A KR 20140116879 A KR20140116879 A KR 20140116879A KR 1020147020364 A KR1020147020364 A KR 1020147020364A KR 20147020364 A KR20147020364 A KR 20147020364A KR 20140116879 A KR20140116879 A KR 20140116879A
Authority
KR
South Korea
Prior art keywords
aminobutane
sulfonic acid
angiotensin
pharmaceutically acceptable
enalapril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147020364A
Other languages
English (en)
Korean (ko)
Inventor
꺄떼린 로랑스-꼬르떼쓰
야니끄 마끄
지 갸오-데스리앙
파브리스 발라부완느
리오넬 세갸르
Original Assignee
깡뚬 제노믹스
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깡뚬 제노믹스, 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) filed Critical 깡뚬 제노믹스
Publication of KR20140116879A publication Critical patent/KR20140116879A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147020364A 2011-12-21 2012-12-21 (3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합 Ceased KR20140116879A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306735 2011-12-21
EP11306735.9 2011-12-21
PCT/EP2012/076607 WO2013092984A1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

Publications (1)

Publication Number Publication Date
KR20140116879A true KR20140116879A (ko) 2014-10-06

Family

ID=47522577

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020364A Ceased KR20140116879A (ko) 2011-12-21 2012-12-21 (3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합

Country Status (25)

Country Link
US (1) US10959938B2 (https=)
EP (1) EP2793878B1 (https=)
JP (2) JP6212500B2 (https=)
KR (1) KR20140116879A (https=)
CN (2) CN104220062B (https=)
AU (1) AU2012356895B2 (https=)
BR (1) BR112014015276B1 (https=)
CA (1) CA2859704C (https=)
CY (1) CY1118711T1 (https=)
DK (1) DK2793878T3 (https=)
EA (1) EA028718B1 (https=)
ES (1) ES2619027T3 (https=)
HR (1) HRP20170267T1 (https=)
HU (1) HUE033403T2 (https=)
IL (1) IL233156B (https=)
IN (1) IN2014DN05787A (https=)
LT (1) LT2793878T (https=)
MX (1) MX345469B (https=)
PL (1) PL2793878T3 (https=)
PT (1) PT2793878T (https=)
RS (1) RS55774B1 (https=)
SI (1) SI2793878T1 (https=)
SM (1) SMT201700156T1 (https=)
WO (1) WO2013092984A1 (https=)
ZA (1) ZA201405266B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015276B1 (pt) * 2011-12-21 2020-09-29 Quantum Genomics Combinação de (3s,3s) 4,4-dissulfanodiilbis(ácido 3-aminobutano 1-sulfônico) e um segundo agente anti-hipertensivo
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素－血管收縮素系統阻斷劑之醫藥組合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
ES2309336T3 (es) * 2002-07-16 2008-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derivados de 4,4-ditiobis-(3-aminobutano-1-sulfanatos) nuevos y composiciones que los contienen.
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
BR112014015276B1 (pt) * 2011-12-21 2020-09-29 Quantum Genomics Combinação de (3s,3s) 4,4-dissulfanodiilbis(ácido 3-aminobutano 1-sulfônico) e um segundo agente anti-hipertensivo

Also Published As

Publication number Publication date
MX2014007547A (es) 2014-08-01
CA2859704A1 (en) 2013-06-27
NZ627251A (en) 2015-08-28
IL233156B (en) 2018-05-31
US20150320703A1 (en) 2015-11-12
US10959938B2 (en) 2021-03-30
JP6726138B2 (ja) 2020-07-22
JP6212500B2 (ja) 2017-10-11
HRP20170267T1 (hr) 2017-05-19
JP2015506338A (ja) 2015-03-02
BR112014015276A2 (pt) 2017-06-13
JP2017222696A (ja) 2017-12-21
PT2793878T (pt) 2017-03-23
MX345469B (es) 2017-02-01
WO2013092984A1 (en) 2013-06-27
PL2793878T3 (pl) 2017-08-31
ZA201405266B (en) 2016-06-29
SI2793878T1 (sl) 2017-07-31
CN109464432A (zh) 2019-03-15
SMT201700156T1 (it) 2017-05-08
IL233156A0 (en) 2014-07-31
HUE033403T2 (en) 2017-11-28
HK1203051A1 (en) 2015-10-16
DK2793878T3 (en) 2017-03-27
CN104220062B (zh) 2018-06-15
LT2793878T (lt) 2017-05-25
EP2793878B1 (en) 2017-02-01
EP2793878A1 (en) 2014-10-29
ES2619027T3 (es) 2017-06-22
AU2012356895B2 (en) 2017-05-25
IN2014DN05787A (https=) 2015-05-15
CN104220062A (zh) 2014-12-17
BR112014015276A8 (pt) 2017-06-13
BR112014015276B1 (pt) 2020-09-29
CY1118711T1 (el) 2017-07-12
EA201400724A1 (ru) 2014-09-30
RS55774B1 (sr) 2017-07-31
CA2859704C (en) 2020-04-28
EA028718B1 (ru) 2017-12-29
AU2012356895A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
TWI539950B (zh) 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑
US20030180355A1 (en) Combination therapy for hypertension
KR20140116879A (ko) (3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합
MX2012013054A (es) Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso.
HK1203051B (en) Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
TWI281858B (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
NZ627251B2 (en) Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
US20230233492A1 (en) Pharmaceutical combination comprising a brain aminopeptidase a inhibitor, a diuretic and a blocker of the systemic renin-angiotensin system
WO2011027021A1 (en) A method for the treatment of hypertension
EP1382334A1 (en) Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
OA21056A (en) Pharmaceutical combination comprising a brain aminopeptidase a inhibitor, a diuretic and a blocker of the systemic reninangiotensin system.
TW201304775A (zh) 使用依普羅沙坦與氨氯地平治療高血壓的組成物和方法
JP2006504800A (ja) リシノプリル／レルカニジピンの組み合わせ治療

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140721

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190315

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200113

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190315

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200113

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190910

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200309

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200213

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20200113

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190910

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190315

X601 Decision of rejection after re-examination